Kadimastem Ltd (KDST) - Net Assets
Based on the latest financial reports, Kadimastem Ltd (KDST) has net assets worth ILA-50.85 Million ILA (≈ $-136.34K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA1.55 Million ≈ $4.17K USD) and total liabilities (ILA52.41 Million ≈ $140.50K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Kadimastem Ltd's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA-50.85 Million |
| % of Total Assets | -3272.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 503.81 |
Kadimastem Ltd - Net Assets Trend (2010–2024)
This chart illustrates how Kadimastem Ltd's net assets have evolved over time, based on quarterly financial data. See KDST cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Kadimastem Ltd (2010–2024)
The table below shows the annual net assets of Kadimastem Ltd from 2010 to 2024. For live valuation and market cap data, see Kadimastem Ltd (KDST) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA-29.15 Million ≈ $-78.14K |
-568.49% |
| 2023-12-31 | ILA-4.36 Million ≈ $-11.69K |
-1437.42% |
| 2022-12-31 | ILA326.00K ≈ $873.99 |
-97.88% |
| 2021-12-31 | ILA15.38 Million ≈ $41.24K |
+290.80% |
| 2020-12-31 | ILA-8.06 Million ≈ $-21.61K |
+32.96% |
| 2019-12-31 | ILA-12.03 Million ≈ $-32.24K |
-278.48% |
| 2018-12-31 | ILA6.74 Million ≈ $18.06K |
+57.43% |
| 2017-12-31 | ILA4.28 Million ≈ $11.47K |
+150.02% |
| 2016-12-31 | ILA-8.56 Million ≈ $-22.94K |
-736.36% |
| 2015-12-31 | ILA-1.02 Million ≈ $-2.74K |
-166.13% |
| 2014-12-31 | ILA1.55 Million ≈ $4.15K |
-78.74% |
| 2013-12-31 | ILA7.28 Million ≈ $19.50K |
+207.36% |
| 2012-12-31 | ILA-6.78 Million ≈ $-18.17K |
-95.44% |
| 2011-12-31 | ILA-3.47 Million ≈ $-9.29K |
-77.25% |
| 2010-12-31 | ILA-1.96 Million ≈ $-5.24K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kadimastem Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23220800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA245.07 Million | % |
| Total Equity | ILA-29.15 Million | 100.00% |
Kadimastem Ltd Competitors by Market Cap
The table below lists competitors of Kadimastem Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
$22.18 Million |
|
Fiplasto SA
BA:FIPL
|
$22.18 Million |
|
Xu Yuan Packaging Technology Co Ltd
TWO:8421
|
$22.18 Million |
|
Lyka Labs Limited
NSE:LYKALABS
|
$22.19 Million |
|
Eden Innovations Ltd
AU:EDE
|
$22.16 Million |
|
Desert Mountain Energy Corp
V:DME
|
$22.13 Million |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
$22.13 Million |
|
NexgenRX Inc.
V:NXG
|
$22.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kadimastem Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,360,000 to -29,146,000, a change of -24,786,000.
- Net loss of 26,552,000 reduced equity.
- Other factors increased equity by 1,766,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-26.55 Million | -91.1% |
| Other Changes | ILA1.77 Million | +6.06% |
| Total Change | ILA- | % |
Book Value vs Market Value Analysis
This analysis compares Kadimastem Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA0.75 | ILA2794.00 | x |
| 2018-12-31 | ILA0.71 | ILA2794.00 | x |
| 2019-12-31 | ILA-1.17 | ILA2794.00 | x |
| 2020-12-31 | ILA-0.41 | ILA2794.00 | x |
| 2021-12-31 | ILA0.46 | ILA2794.00 | x |
| 2022-12-31 | ILA0.01 | ILA2794.00 | x |
| 2023-12-31 | ILA-1.04 | ILA2794.00 | x |
| 2024-12-31 | ILA-6.95 | ILA2794.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kadimastem Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-762.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -173.39% | -5255.83% | 0.02x | 1.71x | ILA-13.34 Million |
| 2014 | -981.97% | -4703.10% | 0.03x | 7.77x | ILA-15.35 Million |
| 2015 | 0.00% | -1659.92% | 0.13x | 0.00x | ILA-16.96 Million |
| 2016 | 0.00% | -1172.81% | 0.36x | 0.00x | ILA-19.12 Million |
| 2017 | -500.65% | -3132.75% | 0.06x | 2.83x | ILA-21.86 Million |
| 2018 | -355.71% | 0.00% | 0.00x | 2.17x | ILA-24.64 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-23.88 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-20.90 Million |
| 2021 | -170.82% | 0.00% | 0.00x | 1.78x | ILA-27.81 Million |
| 2022 | -6968.71% | 0.00% | 0.00x | 38.31x | ILA-22.75 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-11.57 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-23.64 Million |
Industry Comparison
This section compares Kadimastem Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,169,042
- Average return on equity (ROE) among peers: -255.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kadimastem Ltd (KDST) | ILA-50.85 Million | -173.39% | N/A | $22.18 Million |
| BioLine RX Ltd (BLRX) | $22.03 Million | -140.41% | 1.15x | $11.20 Million |
| BioLight Life Sciences Ltd (BOLT) | $22.11 Million | -85.20% | 0.55x | $7.63 Million |
| Bonus Biogroup (BONS) | $604.00K | -1855.46% | 6.49x | $117.42 Million |
| Can Fite Biopharma Ltd (CANF) | $3.29 Million | -203.55% | 0.49x | $5.25 Million |
| Clal Biotechnology Industries Ltd (CBI) | $1.11 Billion | 7.88% | 0.13x | $11.98 Million |
| Compugen (CGEN) | $106.69 Million | -32.06% | 0.24x | $154.47 Million |
| DNA Biomed Solns (DNA) | $54.33 Million | 33.82% | 0.01x | $29.62 Million |
| Enlivex Therapeutics Ltd (ENLV) | $30.67 Million | -22.89% | 0.07x | $515.68K |
| Evogene (EVGN) | $48.26 Million | -5.23% | 0.34x | $3.83 Million |
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more